These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1390 related items for PubMed ID: 22075171

  • 61. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial.
    Konno R, Tamura S, Dobbelaere K, Yoshikawa H.
    Int J Gynecol Cancer; 2010 Jul; 20(5):847-55. PubMed ID: 20606533
    [Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.
    Schwarz TF, Huang LM, Lin TY, Wittermann C, Panzer F, Valencia A, Suryakiran PV, Lin L, Descamps D.
    Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856
    [Abstract] [Full Text] [Related]

  • 64. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
    Perez S, Iñarrea A, Pérez-Tanoira R, Gil M, López-Díez E, Valenzuela O, Porto M, Alberte-Lista L, Peteiro-Cancelo MA, Treinta A, Carballo R, Reboredo MC, Alvarez-Argüelles ME, Purriños MJ.
    Virol J; 2017 Nov 06; 14(1):214. PubMed ID: 29110680
    [Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
    Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.
    Gynecol Oncol; 2009 Dec 06; 115(3 Suppl):S15-23. PubMed ID: 19819540
    [Abstract] [Full Text] [Related]

  • 68. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF.
    Adv Ther; 2009 Nov 06; 26(11):983-98. PubMed ID: 20024678
    [Abstract] [Full Text] [Related]

  • 69. [Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial].
    Sirakov M.
    Akush Ginekol (Sofiia); 2012 Nov 06; 51(1):63-4. PubMed ID: 22639784
    [No Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D.
    Gynecol Oncol; 2008 Sep 06; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
    Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R, CVT Group.
    Vaccine; 2014 Sep 03; 32(39):5087-97. PubMed ID: 25018097
    [Abstract] [Full Text] [Related]

  • 74. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M.
    PLoS Med; 2017 Sep 03; 14(9):e1002388. PubMed ID: 28926579
    [Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77. HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination.
    Cornall AM, Saville M, Pyman J, Callegari ET, Tan FH, Brotherton JML, Malloy MJ, Tabrizi SN, Wrede CD, Garland SM, VACCINE Study Group.
    Vaccine; 2020 Sep 11; 38(40):6304-6311. PubMed ID: 32736938
    [Abstract] [Full Text] [Related]

  • 78. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials.
    Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, Joura EA, Djursing H, Sigurdsson K, Jefferson L, Alvarez F, Sings HL, Lu S, James MK, Saah A, Haupt RM, FUTURE I, II and III Investigators.
    Int J Cancer; 2011 Mar 15; 128(6):1354-62. PubMed ID: 20506504
    [Abstract] [Full Text] [Related]

  • 79. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ.
    Lancet Oncol; 2012 Jan 15; 13(1):78-88. PubMed ID: 22177579
    [Abstract] [Full Text] [Related]

  • 80. Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial.
    Hu S, Xu X, Zhu F, Hong Y, Hu Y, Zhang X, Pan Q, Zhang W, Zhang C, Yang X, Yu J, Zhu J, Zhu Y, Chen F, Zhao S, Karkada N, Tang H, Bi D, Struyf F, Zhao F.
    Hum Vaccin Immunother; 2021 Apr 03; 17(4):955-964. PubMed ID: 33180670
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 70.